Introduction
The α 1 -adrenergic receptors (α 1 -ARs) are one of the most important members of G protein-coupled receptors (GPCRs), distribute in varieties of organs, tissues and cells, which mediate many important physiological effects in the human body. Until now α 1 -ARs have been divided into at least three subtypes, α 1A , α 1B and α 1D , according to the differences on their gene structure, tissue distribution and pharmacological action (1) (2) (3) .
Studies have confi rmed that α 1 -ARs are closely related to various diseases, such as hypertension, benign prostatic hyperplasia, prostate cancer, and so on (4) (5) (6) . Therefore, it is extremely useful to develop drugs for diseases' examination and clinical diagnosis. So far, researchers have designed and synthesized several α 1 -ARs antagonists, including quinazoline and phenylpiperazine-based derivatives, to prevent and treat diseases related to α 1 -ARs abnormally expressed (7) . However, in the absence of their three-dimensional crystal structures, it is diffi cult to study the biological and pharmacological characteristics of α 1 -ARs with conventional research approaches.
Nowadays, fluorescence analysis technology has developed rapidly in various areas and small-molecule fl uorescent probes have demonstrated high sensitivity and selectivity in the detection of biomacromolecules, such as proteins, enzymes, etc. (8) (9) (10) . Small-molecule fl uorescent probes usually consist of two parts: the pharmacophore that could be bind to the targets, and the fl uorophore that labels the targets with fl uorescent properties.
Based on our previous work (11) (12) (13) (14) , we chose quinazoline and phenylpiperazine moiety as the pharmacophore with high affinity to α 1 -ARs, and naphthalimide as the fl uorophore to provide fl uorescent properties. Biological evaluation confirmed that our probes demonstrated high affinity to α 1 -ARs and reasonable cell fluorescence imaging potential. These interesting results indicated that these fl uorescent probes could be employed as fl uorescent competitive substrates in α 1 -ARs ligand activity screening.
Materials and Methods

Chemicals
In summary, a series of naphthalimide derivatives were well designed and synthesized as fluorescent probes for α 1 -ARs (Scheme 1). In this case, quinazolines and phenylpiperazines acted as pharmacophores, and naphthalimide as fl uorophores.
Optical property
The ideal optical property is of importance for a reasonable fluorescent probe. We firstly measured the optical properties of the synthesized fl uorescent probes. The optical properties were performed on a ThermoFisher Varioskan microplate reader by dissolving the probes in 50 mM PBS, pH 7.4.
Affi nity to α 1 -ARs
Besides the optical properties, the affi nity to the targets is also a key characteristic for fl uorescent probes. Therefore, the affi nity activities to three different adrenergic receptor subtypes (α 1A -, α 1B -and α 1D -AR) of these probes were evaluated by radio-ligand binding test, in which the phentolamine was taken as a positive control.
Fluorescence imaging
HEK293A cells were transfected with α 1A -AR (HEK293A-α 1A -AR cells). The cell lines were grown in DMEM medium supplemented with 10% (v/v) fetal bovine serum (Gibco) in an atmosphere of 5% CO 2 at 37°C.
The cell lines were cultured in 35 mm glass bottom culture dishes (Mat Tek) at 37 °C for 24 h. Then cells were washed with DMEM medium (without fetal bovine serum) and incubated in DMEM medium (without fetal bovine serum) containing the probes for 10 min at 37 °C. Fluorescence imaging was performed on a Zeiss Axio Observer A1.
Results and Discussion
The optical results demonstrated that most of the probes had reasonable optical properties (Table 1) . After being excited, the probes had a large stokes shift. And as we can see in Table 2 , all probes had high affinity to α 1 -ARs at the nM level or even at pM level. Further more, the p henylpiperazine-based probes had about 20-fold higher affinity to α 1 -ARs than phentolamine (1a, 1c, 1e), which were more sensitive and can be a direction for developing other probes or antagonists for α 1 -ARs. The fl uorescent image of 1d ( Figure 1B) showed that the probes could target the α 1 -ARs expressed in the live cells with fluorescence properties at the nanomolar level (20 nM), which would be a direction for developing longer wavelength fluorescent probes for α 1 -ARs. Moreover, these probes could be employed as competitive fl uorescent substrates in α 1 -ARs ligand activity screening.
Conclusion
The current paper describes several naphthalimidebased small-molecule fluorescent probes with high affinity for α 1 -ARs. These results can provide further direction for structure-based fluorescent probes or ligands for α 1 -ARs. Moreover, these fl uorescent probes can help us to understand how α 1 -ARs bind with their ligands and these probes can be expected to be fluorescent competitive substrates for α 1 -ARs activity screening. 
Chemistry: general procedures
All materials were purchased from commercial companies (Aladdin and J&K Scientific) and used without further purification. Twice-distilled water was used throughout all experiments. Mass spectra were performed by the analytical and the mass spectrometry facilities in Drug Analysis Center at Shandong University on Agilent Technologies 1100 infinity HPLC, Applied Biosystems API4000.
1 H-NMR and 13 C-NMR were recorded on a Bruker 300 MHz NMR spectrometer.
The synthetic routes of these probes were in two different ways in Scheme 2 and Scheme 3. We got the key intermediate c3 and d3 through the protection of 3-bromopropan-1-amine and then got the probe 1c and 1d (Scheme 2). The key intermediate of probe 1a, 1b, 1e, and 1f were obtained through the Gabriel reaction (Scheme 3).
Benzyl (3-bromopropyl)carbamate (1)
To a solution of 3-bromopropan-1-amine hydrobromide (5 g, 23 mmol) in 3N NaOH (77 mL) and CHCl 3 (77 mL) was added benzyl carbonochloridate (Cbz-Cl) at 0°C. Then stirred at room temperature overnight. The CHCl 3 layer was separated and washed with H 2 O and brine, then dried with MgSO 4 . The solvent was evaporated in vacuo and separated by column chromatography by using 10% ethyl acetate and 90% petroleum ether to get colorless liquid. ESI-MS calcd for C 11 
Benzyl (3-(4-(2-methoxyphenyl)piperazin-1-yl) propyl)carbamate (c1)
The 1-(2-methoxyphenyl)piperazine (0.83 g, 4.3 mmol), the 1 (1.43 g, 5.3 mmol) (1.2 equiv) and K 2 CO 3 (1.25 g, 9 mmol) (2.1 equiv.) were heated to refl ux in 25 mL CH 3 
3-(4-(2-Methoxyphenyl)piperazin-1-yl)propan-1-amine (c2)
The mixture of compound c1 (0.58 g, 1.5 mmol) and Pd/C (36 mg) in 10 mL CH 3 
2-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (1c)
The naphthalimide (150 mg, 0.76 mmol) and c2 were heated to refl ux in 30 mL EtOH for 3 h, and then cooled to room temperature. Solvent evaporated in vacuo and separated by column chromatography (40% petroleum ether and 60% ethyl acetate) to give the product as yellow solid (294 mg, 90% 
2-(3-(4-(4-Amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (1d)
U sing the general synthetic procedure of 1c above to give the product as yellow solid (153mg, 73% 
2-(2-Bromoethyl)isoindoline-1,3-dione (g)
Potassium phthalimide (0.93 g, 5 mmol) was added to a solution of 1,2-dibromoethane (1.3 mL, 15 mmol) in DMF (8 mL). The mixture was stirred at room temperature overnight and evaporated the solvent in vacuo, the residue dissolved in H 2 O and extracted with ethyl acetate. The organic layer was washed by brine and dried by MgSO 4 . Filtered and solvent evaporated in vacuo, recrystallized from ethyl acetate to give white solid (566 mg, 45 %).
2-(4-Bromobutyl)isoindoline-1,3-dione (h)
Using the general synthetic procedure of g above to give the product h as a white solid (4.1 g, 85 %).
2-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl) isoindoline-1,3-dione (a1)
The compound g (0.36 g, 1.42 mmol), 1-(2-meth oxyphenyl)piperazine (0.35 g, 1.84 mmol) and triethylamine (990 μL, 7.1 mmol) were heated in 20 mL CH 3 CN at 85°C for 6 h. The mixture was cooled to room temperature and solvent evaporated, separated by column chromatography (50% petroleum ether and 50% ethyl acetate) to give the product as yellow solid (0.35 g, 67% 
2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl) isoindoline-1,3-dione (e1)
Usi ng the general synthetic procedure of a1 above to give the product e1 as yellow solid (1. 
2-(2-(4-(4-Amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)ethyl)isoindoline-1,3-dione (b1)
Usi ng the general synthetic procedure of a1 above to give the product b1 as yellow solid (553 mg, 60% 
2-(4-(4-(4-Amino-6,7-dimethoxyquinazolin-2-yl) piperazin-1-yl)butyl)isoindoline-1,3-dione (f1)
Us ing the general synthetic procedure of a1 above to give the product f1 as yellow solid (1. 
2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethanamine hydrochloride (a2)
Hydrazine hydrate (200uL, 3.3 mmol) was added to a solution of a1 (0.3 g, 0.8 mmol) in EtOH (20 mL). The reaction mixture was stirred at 85°C for 3h. Then cooled to room temperature, filtered the precipitate and add HCl/EtOH to the fi ltrate, fi ltered and got the crude product (161 mg, 72 %), which was used without further purifi cation.
4-(4-(2-Methoxyphenyl)piperazin-1-yl)butan-1-amine hydrochloride (e2)
Using the general synthetic procedure of a2 above to give the product e2 as gray solid, which was used without further purifi cation.
2-(4-(2-Aminoethyl)piperazin-1-yl)-6,7-dimeth oxyquinazolin-4-amine hydrochloride (b2)
Using the general synthetic procedure of a2 above to give the product b2 as gray solid, which was used without further purifi cation.
2-(4-(4-Aminobutyl)piperazin-1-yl)-6,7-dimeth oxyquinazolin-4-amine hydrochloride (f2)
Using the general synthetic procedure of a2 above to give the product f2 as gray solid, which was used without further purifi cation.
2-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (1a)
Using the general synthetic procedure of 1c above to give the product 1a as faint yellow solid (112 mg, 67% 
2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (1e)
Using the general synthetic procedure of 1c above to give the product 1e as faint yellow solid (55mg, 16% 
2-(2-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (1b)
Usi ng the general synthetic procedure of 1c above to give the product 1b as yellow solid (54 mg, 41%). 
